- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Telomir Pharmaceuticals Stock Soars Over 90% On Positive Preclinical Data | 1 | RTTNews | ||
| Fr | Telomir-Aktie schießt nach vielversprechenden Daten zur Krebsbehandlung in die Höhe | 3 | Investing.com Deutsch | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Fr | Telomir Pharmaceuticals stock soars after promising cancer treatment data | 2 | Investing.com | ||
| Fr | Telomir-1 shows stronger epigenetic effects than standard drugs in cancer study | 2 | Investing.com | ||
| Fr | Telomir Pharmaceuticals, Inc: Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin | 210 | ACCESS Newswire | New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in... ► Artikel lesen | |
| Fr | Telomir Pharma Skyrockets Nearly 139% After-Hours As Cancer Drug Shows Breakthrough Results, Beats Chemo In Human Cell Tests | 10 | Benzinga.com | ||
| Do | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 18.06. | Telomir-1 shows anti-aging effects in progeria cell study | 2 | Investing.com | ||
| 18.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging | 224 | ACCESS Newswire | Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals... ► Artikel lesen | |
| 18.06. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 18.06. | EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria | 2 | Benzinga.com | ||
| 11.06. | Telomir-1 zeigt vielversprechende Ergebnisse bei der Umkehrung von Morbus-Wilson-Symptomen | 7 | Investing.com Deutsch | ||
| 11.06. | Telomir-1 shows promise in reversing Wilson's disease symptoms | 3 | Investing.com | ||
| 11.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model | 282 | ACCESS Newswire | Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival.Building on... ► Artikel lesen | |
| 05.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome | 266 | ACCESS Newswire | Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential... ► Artikel lesen | |
| 05.06. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 05.06. | EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder | 4 | Benzinga.com | ||
| 02.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform | 202 | ACCESS Newswire | Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026 MIAMI, FL / ACCESS Newswire / June 2, 2025... ► Artikel lesen | |
| 29.05. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA-Recognized Surrogate Endpoints | 330 | ACCESS Newswire | A unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics MIAMI, FLORIDA / ACCESS Newswire / May... ► Artikel lesen | |
| 29.05. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,25 | +1,64 % | Novo Nordisk, BioNxt Solutions, BioNTech - so heilen Sie Ihr Portfolio mit der Gesundheits-Revolution 2025 | Das globale Gesundheitswesen erlebt 2025 eine Zeitenwende. Klimafolgen, chronische Krankheiten und Pandemienarben fordern Systeme heraus, während Digitalisierung und KI rasant neue Therapien vorantreiben.... ► Artikel lesen | |
| MODERNA | 29,280 | +8,18 % | Aktie von Moderna heute am Aktienmarkt gefragt (28,74 €) | An der US-amerikanischen Börse notiert der Anteilsschein von Moderna derzeit etwas fester. Zuletzt zahlten Investoren für das Papier 28,74 Euro. Die Aktie von Moderna verzeichnet zur Stunde einen Wertanstieg... ► Artikel lesen | |
| VALNEVA | 2,960 | +13,67 % | Rheinmetall Aktie: Neue Kursrallye? - Dazu: Aixtron, GFT, Kontron, K+S, Valneva - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 58,00 | +2,65 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| BAVARIAN NORDIC | 25,730 | +5,02 % | Bavarian Nordic A/S: Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine | COPENHAGEN, Denmark, July 22, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company's application for licensure of the single-dose, virus-like... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,695 | +1,39 % | A Look Ahead: Viking Therapeutics' Earnings Forecast | ||
| GERON | 1,128 | +3,11 % | Geron Corp. Posts Narrower Loss In Q1 | WASHINGTON (dpa-AFX) - Geron Corp. (GERN) posted a first quarter net loss of $19.8 million, or $0.03 per share, compared to a loss of $55.4 million, or $0.09 per share, prior year. Total net... ► Artikel lesen | |
| IMMUNITYBIO | 2,350 | +1,69 % | ImmunityBio's ANKTIVA Gains UK Approval In Bladder Cancer Treatment | ||
| ZAI LAB LTD ADR | 31,800 | -1,24 % | Zai Lab Limited: Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 | -Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Favorable preclinical safety profile, prolonged... ► Artikel lesen | |
| VERASTEM | 4,460 | -0,45 % | XFRA 2VSA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 16,850 | -0,41 % | Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) | ||
| GRAIL | 32,500 | +2,52 % | Grail war NASDAQ-Tagessieger | Der kalifornische Krebstest-Entwickler hat die vor zwei Wochen gefahrene Attacke des Shortsellers Ningi Research zunächst offenbar abgeschüttelt. Der Leerverkäufer hatte Zweifel am späteren Erfolge... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,140 | +0,53 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| ANNOVIS BIO | 2,145 | -2,50 % | Annovis Bio Inc.: Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance | MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| XENON PHARMACEUTICALS | 27,000 | +0,75 % | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing... ► Artikel lesen |
Das Unternehmen TELOMIR PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,29 % bei einem Aktienkurs von 2,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.